Vaccine adverse events linked to virus disrupting ingredient
Use of deoxycholate to chemically disrupt influenza viruses during vaccine manufacture could be linked to adverse reactions in children, a journal reports.
Archives for September 18, 2011
Sponsors overlooking mid-tier CROs in post-marketing
Mid-tier CROs are being squeezed out of the post-marketing sector as sponsors choose providers with more scale or specialisation, market research found.
Alkermes moves to Ireland and lands multimillion dollar manufacturing deal
Alkermes has celebrated the launch of its new Irish drug delivery and formulation business by winning a new multimillion dollar manufacturing contract with a ‘top 10 pharma.’
New growth strategy and supply chain management system in place for SAFC, says president Gilles Cottier
SAFC announced its new aggressive growth strategy, including plans to expand in the developing markets, at its conference in Irvine, Glasgow last week.
Precos to double lab capacity on demand
UK CRO Preclinical Oncology Services Limited (Precos) has announced plans to double laboratory capacity in 2012.
ShangPharma eyes discovery biology growth with mAb deal
ShangPharma’s emerging discovery biology services unit has inked another antibody development partnership with a Chinese biopharm.
Circassia and NanoPass strike up deal over intradermal device
Immunotherapy and vaccine specialist Circassia says its new license agreement with NanoPass Technologies will help its range of allergy products to thrive on the market.
GE Healthcare to invest in biomanufacturing tech
GE Healthcare will expand its range of biomanufacturing technologies under a new oncology-focused investment project.